Moreover, stratifying the whole RA cohort based on the achievement of remission at 6 months of follow-up of CTLA4-Ig treatment, at study entry, RA patients achieving DAS-defined remission had significantly lower IL-6 serum levels (10.8 ± 5.8 pg/ml) compared to RA patients not achieving this outcome (36.6 ± 11.1 pg/ml, p = 0.021), while no significant differences were seen in terms of baseline IL-10 or TGFβ serum levels (Fig. 3B). Here, IL6 is linked to rheumatoid arthritis.